Mutabon Ansiolitico (Amitriptyline Hydrochloride, Perphenazine)

Amitriptyline Hydrochloride / Perphenazine, the active ingredients in Mutabon Ansiolitico, are a tricyclic antidepressant and a phenothiazine antipsychotic presented as an oral tablet for oral use. The combination is indicated for depressive disorders, psychotic depression and schizophrenia in adult patients. GNH USA supplies Mutabon Ansiolitico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mutabon Ansiolitico combines a tricyclic antidepressant and a phenothiazine antipsychotic to treat mood and psychotic disorders. - Depressive disorders: alleviates depressive symptoms and improves mood. - Psychotic depression: reduces both depressive and psychotic features. - Schizophrenia: helps control positive psychotic symptoms such as hallucinations and delusions.

Adverse reactions may occur with the combined formulation.

Common Side Effects: - Dry mouth: reduced salivary flow. - Sedation: drowsiness or fatigue. - Constipation: slowed gastrointestinal motility. - Weight gain: increased appetite or fluid retention. - Orthostatic hypotension: dizziness upon standing. - Blurred vision: transient visual disturbances.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially in high‑dose tricyclic use. - Neuroleptic malignant syndrome: fever, muscle rigidity, autonomic instability. - Seizures: heightened risk in predisposed individuals. - Agranulocytosis: severe drop in white blood cells. - Torsades de pointes: life‑threatening ventricular tachycardia. - Hepatotoxicity: liver enzyme elevation or injury.

Before initiating therapy, consider patient‑specific factors and monitor for safety. - Cardiac assessment: obtain baseline ECG in patients with cardiac history. - CNS depression: avoid alcohol or other sedatives that may enhance drowsiness. - Glaucoma: use cautiously in patients with narrow‑angle glaucoma. - Elderly patients: start at low dose and titrate slowly to reduce fall risk. - Pregnancy and lactation: discuss potential risks with the prescriber; data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Drug‑drug interactions can modify efficacy or increase toxicity.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise amitriptyline levels. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation. - Anticholinergic drugs: increased dry mouth, constipation, urinary retention. - Alcohol: potentiates sedative and hypotensive effects.